⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
Adimab Reports Strong Partnering Year for 2025
prnewswire.com
ALNY
NVO
MRK
LLY
REGN
VRTX
AZN
GSK
BIIB
SCHR
ALEC
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight
globenewswire.com
AMGN
ARWR
IONS
NVS
NVO
MRK
LLY
REGN
ESPR
ALNY
VRTX
XBI
diaTribe Convenes International Consensus to Guide Diabetes Technology Use During Pregnancy
prnewswire.com
BIIB
AMGN
LLY
JNJ
PFE
MRK
BMY
GILD
REGN
AZN
ABBV
SNY
NVO
LULU
GOOG
MSFT
AMZN
META
TSLA
NVDA
XOM
CVX
KO
PEP
MCD
DIS
BA
CAT
GS
JPM
BAC
WFC
C
T
VZ
CMCSA
NFLX
ADBE
CRM
INTC
QCOM
AMD
CSCO
HON
GE
IBM
ORCL
SAP
ACN
MU
AMAT
LRCX
ADI
TXN
NXPI
MRVL
MCHP
PYPL
CMG
SBUX
NKE
HD
PG
UNH
ELV
CVS
CI
HCA
MCK
CAH
CD22 Targeted Therapies Market Research Report 2025-2026: Opportunities Lie in Developing Precise CD22 Targeted Therapies for Blood Cancers, with Over 20 Ongoing Clinical Trials
globenewswire.com
PFE
AZN
UMBF
CELC
REGN
Kiniksa Pharmaceuticals Provides Corporate Update
globenewswire.com
KNSA
REGN
Alamar Biosciences gibt Abschluss der überzeichneten Wandelanleihe-Finanzierung und Erweiterung des Führungsteams bekannt USA - Deutsch USA - Français USA - English APAC - English USA - English USA - čeština
prnewswire.com
AMGN
ILMN
VRTX
RIVN
TROW
PRGS
ALNY
REGN
GILD
BMY
MRK
ABBV
AZN
SNY
NVS
XRAY
EVTC
MYGN
RVTY
VTRS
BIIB
MDLZ
PFE
SNDX
EXAS
CRSP
NTRA
ON
IDXX
MDT
SYK
ISRG
DXCM
COO
AMZN
GOOG
MSFT
NVDA
IBM
INTC
QCOM
AMD
MU
ADBE
CRM
ORCL
SAP
CSCO
ACN
HPQ
DELL
MSCI
FIS
PAYX
ADP
BBBY
ROST
TJX
MCHP
NXPI
SNPS
CDNS
WDC
STX
KLAC
LRCX
AMAT
CTAS
PAYC
NOW
DDOG
ZS
PANW
FTNT
SNOW
PYPL
V
MA
AXP
BAC
JPM
WFC
C
GS
MS
SCHW
ELAN
ZTS
ALGN
XOM
CVX
KO
PEP
MCD
DIS
CMCSA
VZ
T
NFLX
Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
prnewswire.com
REGN
Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo ®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
businesswire.com
REGN
New Spherix Patient Research Shows Nearly Half of Atopic Dermatitis Patients Report Major Quality-of-Life Impact Despite Expanding Treatment Options
globenewswire.com
REGN
SNY
SPRX
Enara Bio Enters 2026 with Dark Antigen Licensing to Boehringer Ingelheim, Appointment of Chief Medical Officer and Plans to Advance DARKFOX T-cell Engager into First-in-Human Studies
globenewswire.com
REGN